Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

Young Tae Kim; Sang Wun Kim; Bo Sung Yoon; Hye Jin Cho; Eun Ji Nahm; Sung Hoon Kim; Jae Hoon Kim; Jae Wook Kim

doi:10.1016/j.ygyno.2006.11.014

Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

Young Tae Kim, Sang Wun Kim, Bo Sung Yoon, Hye Jin Cho, Eun Ji Nahm, Sung Hoon Kim, Jae Hoon Kim, Jae Wook Kim

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

89 Citations (Scopus)

Abstract

Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.

Original language	English
Pages (from-to)	199-204
Number of pages	6
Journal	Gynecologic Oncology
Volume	105
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2006.11.014
Publication status	Published - 2007 Apr

Bibliographical note

Funding Information:
This study was supported by the Brain Korea (BK) 21 Project for Medical Sciences, Yonsei University and a grant of the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (0412-CR01-0704-0001). We thank H.K.Park (Choongwae Pharma. Corp.) for his assistance in preparing this work.

All Science Journal Classification (ASJC) codes

Oncology
Obstetrics and Gynaecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2006.11.014

Cite this

@article{fd76e67558d944d1b6a45f5c7a45c159,

title = "Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy",

abstract = "Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.",

author = "Kim, {Young Tae} and Kim, {Sang Wun} and Yoon, {Bo Sung} and Cho, {Hye Jin} and Nahm, {Eun Ji} and Kim, {Sung Hoon} and Kim, {Jae Hoon} and Kim, {Jae Wook}",

note = "Funding Information: This study was supported by the Brain Korea (BK) 21 Project for Medical Sciences, Yonsei University and a grant of the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (0412-CR01-0704-0001). We thank H.K.Park (Choongwae Pharma. Corp.) for his assistance in preparing this work.",

year = "2007",

month = apr,

doi = "10.1016/j.ygyno.2006.11.014",

language = "English",

volume = "105",

pages = "199--204",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

AU - Kim, Young Tae

AU - Kim, Sang Wun

AU - Yoon, Bo Sung

AU - Cho, Hye Jin

AU - Nahm, Eun Ji

AU - Kim, Sung Hoon

AU - Kim, Jae Hoon

AU - Kim, Jae Wook

N1 - Funding Information: This study was supported by the Brain Korea (BK) 21 Project for Medical Sciences, Yonsei University and a grant of the Korean Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (0412-CR01-0704-0001). We thank H.K.Park (Choongwae Pharma. Corp.) for his assistance in preparing this work.

PY - 2007/4

Y1 - 2007/4

N2 - Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.

AB - Objective.: The incidence of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy is estimated to be more than 50%. Transfusion has been the mainstay of hematologic support with its inherent hazards including infection and transfusion reaction. The aim of this study was to examine the impact of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients undergoing concurrent chemoradiotherapy. Methods.: From Oct. 2003 to Dec. 2005, 75 patients were treated with platinum-based concurrent chemoradiotherapy. Thirty patients received 200 mg of iron sucrose intravenously (study group) and 45 patients did not receive it (control group). Results.: In the study group, only 12 (40.0%) patients required blood transfusions, whereas 29 (64.0%) patients in the control group needed blood transfusions (P = 0.04). Mean transfusion units were 1.87 units in the study group and 3.58 units in the control group (P = 0.04). Conclusion.: This study showed that intravenous supply of iron sucrose could decrease transfusion requirement and increase serum hemoglobin level in patients with cervical carcinoma undergoing concurrent chemoradiotherapy. Therefore, intravenously administered iron sucrose would be effective in the prevention of anemia of cervical cancer patients receiving concurrent chemoradiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=33947312849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947312849&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.11.014

DO - 10.1016/j.ygyno.2006.11.014

M3 - Article

C2 - 17234260

AN - SCOPUS:33947312849

SN - 0090-8258

VL - 105

SP - 199

EP - 204

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 1

ER -

Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this